Drug Overview:
Cabozantinib-s-malate, marketed as the potent multitargeted “smart drug” and targeted therapy Cabometyx/Cometriq, represents a paradigm shift in precision oncology for advanced solid tumors driven by dysregulated kinase signaling pathways. This oral small-molecule inhibitor simultaneously suppresses multiple receptor tyrosine kinases critical for tumor proliferation, angiogenesis, metastasis, and immune evasion, delivering superior progression-free survival benefits in VEGF therapy-refractory cancers across renal cell carcinoma, hepatocellular carcinoma, and thyroid malignancies prevalent in US and European patient populations.
- Generic name: Cabozantinib-s-malate
- US Brand names: Cabometyx® (20, 40, 60 mg tablets for RCC/HCC/DTC); Cometriq® (20 mg capsules for MTC)
- Drug Class: Multikinase inhibitor (targeted therapy against VEGFR2/3, MET, RET, AXL, KIT, ROS1, TRKB, TIE2)
- Route of Administration: Oral (tablets/capsules on an empty stomach)
- FDA Approval Status: Initial approval November 2012 (Cometriq® medullary thyroid cancer); expanded November 2016 (Cabometyx® advanced RCC); January 2021 (HCC + atezolizumab); 2025 (radioactive iodine-refractory differentiated thyroid cancer post-TKI)
What Is It and How Does It Work? (Mechanism of Action)
Cabozantinib-s-malate exerts its targeted therapy effects as a potent ATP-competitive inhibitor binding the kinase domains of multiple receptor tyrosine kinases, preventing ligand-induced dimerization, autophosphorylation, and activation of convergent oncogenic signaling cascades. This “smart drug” uniquely disrupts the tumor-stroma-immune axis through simultaneous angiogenesis blockade, epithelial-mesenchymal transition (EMT) inhibition, and enhanced immune infiltration.
- VEGFR2/3 inhibition (IC50 0.035 nM): Blocks VEGF-A/C/D ligand binding → prevents PLCγ1-PKC-MAPK/ERK and PI3K-AKT-mTOR pathway activation in endothelial cells → inhibits vascular permeability/proliferation/migration, starving hypoxic tumors
- MET/AXL blockade (IC50 1.3/7 nM): Disrupts HGF/SF and Gas6 ligand signaling → inhibits FAK/Src-mediated focal adhesion turnover, suppresses EMT transcription factors (Snail/Slug/Twist), prevents tumor invasion/metastasis
- RET inhibition (IC50 5.2 nM): Targets mutated RET fusions (M918T/C634) → blocks ligand-independent constitutive dimerization → halts RAS-RAF-MEK-ERK and PI3K-AKT cascades driving thyroid neuroendocrine proliferation
- Additional RTKs (KIT/TRKB/ROS1 IC50 4-40 nM): Suppresses SCF-induced mast cell recruitment, neural invasion (TRKB), and fusion-driven oncogenesis (ROS1); modulates TAM receptors enhancing macrophage M2→M1 polarization
- Convergent effects: Downregulates mTORC1/2 → G1/S arrest via 4EBP1/eIF4E; upregulates pro-apoptotic BIM/PUMA; normalizes tumor vasculature improving immunotherapy penetration
FDA Approved Clinical Indications
Cabozantinib-s-malate demonstrates broad FDA approvals exclusively for advanced refractory solid tumors, with emerging biomarkers (MET amplification, RET fusions) predicting exceptional responses in precision medicine frameworks.
Oncological uses:
- Advanced renal cell carcinoma (RCC) following prior anti-angiogenic therapy or as first-line monotherapy
- Unresectable, locally advanced, or metastatic hepatocellular carcinoma (HCC) in combination with atezolizumab following prior sorafenib
- Progressive, metastatic medullary thyroid cancer (MTC)
- Radioactive iodine-refractory differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy.
Non-oncological uses:
None
Dosage and Administration Protocols
Continuous daily oral dosing requires strict fasting conditions (1 hour before/2 hours after meals) to optimize bioavailability; sequential dose reductions (60→40→20 mg) manage >80% of grade 3+ toxicities effectively.
| Patient Population | Standard Dose | Frequency | Dose Adjustments |
| RCC monotherapy | 60 mg (three 20 mg tablets) | Orally once daily continuous | First reduction: 40 mg; second: 20 mg; permanent discontinue intolerable Grade 4 |
| HCC + atezolizumab | 60 mg | Once daily continuous | Hepatic Child-Pugh A: full dose; B: start 40 mg; C contraindicated |
| MTC (Cometriq capsules) | 140 mg (7 × 20 mg) | Once daily (4 weeks on/2 off historical) | Strong CYP3A4 inducers: increase 40 mg (max 80 mg); QTc >500 ms: hold/reduce |
| Renal Impairment | No adjustment | CrCl ≥30 mL/min | CrCl <30: monitor, no data |
| Hepatic Impairment | Child-Pugh A: 60 mg; B: 40 mg | Same | C: contraindicated |
Clinical Efficacy and Research Results
Phase 3 METEOR (RCC; NCT01865747), COSMIC-321 (HCC; NCT03713593), and CheckMate 9ER (RCC+nivo; NCT03141177) trials with 2020-2025 mature data established survival standards; CONTACT-02 (mCRPC 2025) expands indications.
| Trial/Indication | PFS Benefit | OS Benefit | ORR |
| METEOR (RCC 2L) | 21.4 vs 7.4 mo (HR 0.51) | 21.4 vs 16.5 mo (HR 0.66) | 17% vs 3% |
| COSMIC-321 (HCC) | 6.8 vs 4.2 mo (HR 0.60) | 15.4 vs 8.6 mo (HR 0.69) | 11% vs 2% |
| CheckMate 9ER (RCC 1L+nivo) | NR vs 11.9 mo (HR 0.51) | 2-yr 79.7% vs 68.8% | 55.7% vs 27.1% |
Safety Profile and Side Effects
Black Box Warning:
Severe hemorrhage (including fatal GI bleeding) and arterial/venous thromboembolic events (stroke, MI, PE) reported; GI perforation/fistula risk elevated. Discontinue for life-threatening hemorrhage; monitor BP closely.
Common Side Effects (>10%)
| Adverse Event | Incidence | Management |
| Hypertension | 36-74% | ACEi/ARB titration <140/90 mmHg; amlodipine add-on |
| Diarrhea | 42-74% | Loperamide 4 mg stat + 2 mg PRN (≤16 mg/day); hold Grade 3+ |
| Fatigue | 56% | Scheduled rest; dose interruption Grade 3+ |
| PPE/rash | 35-57% | Urea 10-20% cream BID prophylaxis; doxycycline 100 mg BID |
| Weight loss | 25-48% | Protein supplements; dietician referral <10% loss |
Serious Adverse Events
- Hemorrhage (3-10% Grade 3/4; hold Grade 3, discontinue Grade 4; urgent endoscopy for melena/hematemesis)
- Thromboembolism (3-7% VTE/1-3% arterial; baseline D-dimer; LMWH if cancer-associated thrombosis)
- GI perforation/fistula (1-3%; abdominal CT, NPO, surgical consult; permanent discontinuation)
- Hepatotoxicity (3-9% Grade 3/4 ALT/AST; weekly LFTs first 8 weeks, hold >8x ULN)
Research Areas
Peer-reviewed research in 2026 focuses on establishing Cabozantinib as a backbone for immunotherapy combinations and expanding its use into hormone-refractory and neuroendocrine cancers. A primary area of study is the CONTACT-02 Phase 3 trial, which recently validated the combination of cabozantinib and atezolizumab in metastatic castration-resistant prostate cancer (mCRPC), demonstrating a statistically significant improvement in progression-free survival (PFS), particularly in patients with high-risk liver metastases. In radioiodine-refractory differentiated thyroid cancer, 2026 exploratory analyses from the COSMIC-311 trial have proven that cabozantinib remains highly effective regardless of BRAF mutation status, securing its role as a versatile second-line standard. Furthermore, the NCT03375320 Phase 3 trial results (2025/2026) have established cabozantinib as a potent option for pancreatic neuroendocrine and carcinoid tumors that have progressed on previous therapies. Current molecular research is also refining predictive biomarkers, moving beyond traditional MET/AXL expression to investigate how microvascular and mast cell density within the tumor microenvironment can predict long-term durability of response.
Disclaimer: This information should be considered exploratory unless supported by definitive clinical evidence. While it represents significant frontiers in medical research, it is currently in the preclinical or early investigational phase and is not yet applicable to practical or professional clinical scenarios.
Patient Management and Practical Recommendations
Proactive hypertension/PPE/hepatotoxicity management sustains >70% dose intensity; multidisciplinary cardio-onco/derm/vascular support essential for long-term adherence.
Pre-treatment Tests
- BP (target <140/90), ECG (QTcF <450/470 ms M/F), TTE (LVEF >50%)
- CBC, CMP (LFTs/bilirubin), UA (1+ protein OK), TSH/FT4, dental evaluation
- Urine/serum pregnancy test (Category D teratogen)
Precautions During Treatment
- Weekly BP/LFTs/CBC/UA first 8 weeks → biweekly; hold Grade 3+ tox (resume 40 mg)
- Avoid strong CYP3A4 perpetrators; monitor dentition (bisphosphonate osteonecrosis risk)
- ECG if syncope, palpitations, concomitant QT drugs
Do’s and Don’ts
- Do take 1h fasted with ≥8 oz water; consistent daily timing
- Do elevate legs, compression stockings (edema 40%); moisturize bid PPE prevention
- Don’t eat 2h before/1h after; grapefruit juice
- Don’t breastfeed during +4 months post-therapy
Legal Disclaimer
This guide provides general information about cabozantinib-s-malate and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult qualified healthcare providers for individualized recommendations considering complete clinical profiles, comorbidities, and guideline updates. Treatment decisions must balance risks/benefits; this content neither endorses nor contraindicates specific therapies.
